Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Tax Provisions (2019 - 2024)

C4 Therapeutics has reported Tax Provisions over the past 4 years, most recently at $131000.0 for Q4 2024.

  • For Q4 2024, Tax Provisions fell 53.21% year-over-year to $131000.0; the TTM value through Dec 2024 reached $131000.0, down 89.79%, while the annual FY2025 figure was $121000.0, 7.63% down from the prior year.
  • Tax Provisions for Q4 2024 was $131000.0 at C4 Therapeutics, down from $280000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $1.0 million in Q3 2023 and troughed at -$168000.0 in Q2 2020.
  • A 3-year average of $112571.4 and a median of -$124000.0 in 2020 define the central range for Tax Provisions.
  • On a YoY basis, Tax Provisions climbed as much as 29.17% in 2020 and fell as far as 125.69% in 2020.
  • Year by year, Tax Provisions stood at -$124000.0 in 2020, then skyrocketed by 325.81% to $280000.0 in 2023, then crashed by 53.21% to $131000.0 in 2024.
  • Business Quant data shows Tax Provisions for CCCC at $131000.0 in Q4 2024, $280000.0 in Q4 2023, and $1.0 million in Q3 2023.